Monograph
N02AE01 - Buprenorphine |
Not porphyrinogenic |
NP |
Rationale
Substrate of CYP 3A4. Inhibitor os CYPs 3A4, 2D6, 1A1, 1A2, 2B6, 2C19, 2C8, 2C9, 2E1. Several references consider it safe. Significant clinical experience points to non-porphyrinogenicity.
Chemical description
Partial opioid antagonist used in postoperative pain and in Sweden also repeatedly in acute porphyric crises. Metabolized by CYP 3A4. MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-53: use EPI-list: safe Australian list: safe. South African list: use French list: use Without adverse reaction frequently used during acute porphyric crises (Sweden).
IPNet drug reports
Uneventful use reported in 6 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Buprenorfine · BuTrans · Temgesic · Transtec 
Temgesic · Temgesic Sublingualis · Transtec 
Buprenorfina · Buprex · Feliben · Gexana · Transtec 
Busetalt · Busette · Durlevatec · Septrapat · Temgesic · Transtec 
Bunov · Bupeaze · Buplast · Bupramyl · Buprenorphine · Busiete · Butec · BuTrans · Buvidal · Carlosafine · Gabup · Hapoctasin · Natzon · Panitaz · Prefibin · Prenotrix · Rebrikel · Reletrans · Relevtec · Sevodyne · Subutex · Temgesic · Tephine · Transtec · Turgeon 
Buprefarm · Bupremyl · Buprenorphin · Buprenorphine · BuTrans · Norspan · Norvipren · Subutex · Temgesic 
Bugnanto · Buprefarm · Buprenorphine · Norspan · Temgesic 
Bunondol · Bunorfin · Melodyn · Transtec 
Buprenorphin · Temgesic · Temgesic Sublingualis · Transtec 
Buprenorphine · Norspan 
Buprefarm · Bupremyl · Buprenorphine · Norspan · Temgesic 
Transtec
© NAPOS 2025